Julia Levy | Academic Influence

Julia Levy's AcademicInfluence.com Rankings

Julia Levy

Biology

#4712

World Rank

#7003

Historical Rank

Immunology

#541

World Rank

#558

Historical Rank

biology Degrees

Download Badge

Biology

Julia Levy's Degrees

Masters Microbiology University of British Columbia
Bachelors Biology McGill University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Julia Levy Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Julia Levy is a Canadian microbiologist, immunologist, educator and entrepreneur. Early life and education The daughter of Guillaume Albert and Dorothy Frances Coppens, she was born Julia Coppens in Singapore. In 1940, her father sent her mother and his two daughters from their home in Indonesia to Vancouver, British Columbia, where he joined them at the end of World War II after he was released from a Japanese prisoner of war camp. Her early education was in Canada. She studied immunology and bacteriology at the University of British Columbia, earning a BA in 1955. Levy received a PhD in experimental pathology from the University of London in 1958. In 1959, she returned to the University of British Columbia as an assistant professor, later becoming full professor.

(See a Problem?)

Julia Levy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. (1983) (291)
LIPOSOMAL DELIVERY OF A PHOTOSENSITIZER, BENZOPORPHYRIN DERIVATIVE MONOACID RING A (BPD), TO TUMOR TISSUE IN A MOUSE TUMOR MODEL (1993) (182)
Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. (1994) (170)
Preliminary studies on a more effective phototoxic agent than hematoporphyrin. (1987) (167)
Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. (1990) (136)
Stimulation of Stress-activated Protein Kinase and p38 HOG1 Kinase in Murine Keratinocytes following Photodynamic Therapy with Benzoporphyrin Derivative* (1996) (131)
Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein (1985) (123)
In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. (1976) (119)
Development of a model to demonstrate photosensitizer‐mediated viral inactivation in blood (1990) (112)
THE EFFECTS OF PLASMA LIPOPROTEINS ON in vitro TUMOR CELL KILLING and in vivo TUMOR PHOTOSENSITIZATION WITH BENZOPORPHYRIN DERIVATIVE (1991) (111)
Photosensitizers in photodynamic therapy. (1994) (110)
Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. (1985) (110)
Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. (1991) (105)
Suppressor cells in the spleens of tumor-bearing mice: enrichment by centrifugation on hypaque-ficoll and characterization of the suppressor population. (1976) (104)
Photodynamic therapy induces caspase-3 activation in HL-60 cells (1997) (101)
Influence of tumor size and surgical resection on cell-mediated immunity in mice. (1974) (101)
THE PLASMA DISTRIBUTION OF BENZOPORPHYRIN DERIVATIVE and THE EFFECTS OF PLASMA LIPOPROTEINS ON ITS BIODISTRIBUTION (1990) (90)
In vitro EVALUATION OF PHOTOTOXIC PROPERTIES OF FOUR STRUCTURALLY RELATED BENZOPORPHYRIN DERIVATIVES (1990) (89)
Characterization of suppressor cells in mice bearing syngeneic mastocytoma. (1977) (86)
Photosensitizers as virucidal agents. (1993) (84)
New Applications in Photodynamic Therapy Introduction (1996) (83)
Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy (1999) (83)
Development of technology for linking photosensitizers to a model monoclonal antibody. (1990) (82)
Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. (1999) (81)
Nuclear factor-κB activation by the photochemotherapeutic agent verteporfin (2000) (74)
The use of the enzyme-linked immunosorbent assay (ELISA) for the detection and quantification of specific antibody from cell cultures. (1979) (71)
STRESS PROTEIN EXPRESSION IN MURINE TUMOR CELLS FOLLOWING PHOTODYNAMIC THERAPY WITH BENZOPORPHYRIN DERIVATIVE (1993) (66)
The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. (1980) (62)
Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. (1998) (55)
Immunomodulatory aspects of photodynamic therapy. (1998) (54)
Prolonged skin allograft survival after photodynamic therapy associated with modification of donor skin antigenicity. (1997) (52)
An immunocytochemical investigation with monoclonal antibodies to somatostatin (2004) (52)
Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. (1990) (50)
Photodynamic therapy; a comparison with other immunomodulatory treatments of adjuvant‐enhanced arthritis in MRL‐lpr mice (1994) (49)
MOUSE SKIN PHOTOSENSITIZATION WITH BENZOPORPHYRIN DERIVATIVES AND PHOTOFRIN®: MACROSCOPIC AND MICROSCOPIC EVALUATION (1991) (49)
Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. (1999) (48)
Overexpression of Bcl‐XL prevents caspase‐3‐mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD‐MA (1998) (48)
Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. (2000) (48)
Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. (1991) (48)
Two distinct populations of suppressor cells in the spleens of mice bearing methylcholanthrene-induced tumors. (1978) (47)
Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative. (1992) (47)
The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice. (1994) (46)
Photodynamic therapy inhibits cell adhesion without altering integrin expression. (1997) (46)
Photodynamic Alteration of the Surface Receptor Expression Pattern of Murine Splenic Dendritic Cells (1999) (45)
IL-10 Contributes to the Inhibition of Contact Hypersensitivity in Mice Treated with Photodynamic Therapy (2000) (45)
In vitro AND in vivo UPTAKE OF BENZOPORPHYRIN DERIVATIVE INTO HUMAN AND MINISWINE ATHEROSCLEROTIC PLAQUE (1993) (43)
The induction of nonspecific T suppressor lymphocytes by prostaglandin E1. (1981) (43)
TARGETING ACTIVATED LYMPHOCYTES WITH PHOTODYNAMIC THERAPY: SUSCEPTIBILITY OF MITOGEN‐STIMULATED SPLENIC LYMPHOCYTES TO BENZOPORPHYRIN DERIVATIVE (BPD) PHOTOSENSITIZATION (1995) (41)
Characterization Of Benzoporphyrin Derivative, A New Photosensitizer (1989) (40)
Anti-tumour effects of the sesquiterpene lactone parthenin. (1982) (39)
Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin (1980) (38)
Photosensitizing efficiency of two regioisomers of the benzoporphyrin derivative monoacid ring A (BPD-MA). (1992) (38)
Photodynamic Treatment with Benzoporphyrin Derivative Monoacid Ring A Produces Protein Tyrosine Phosphorylation Events and DNA Fragmentation in Murine P815 Cells (1998) (37)
WAVELENGTH‐DEPENDENT EFFECTS OF BENZOPORPHYRIN DERIVATIVE MONOACID RING A in vivo AND in vitro (1994) (37)
Uptake of Verteporfin® by articular tissues following systemic and intra‐articular administration (1998) (37)
Delivery of Benzoporphyrin Derivative, a Photosensitizer, into Atherosclerotic Plaque of Watanabe Heritable Hyperlipidemic Rabbits and Balloon‐Injured New Zealand Rabbits (1997) (33)
Transcutaneous Photodynamic Therapy Alters the Development of an Adoptively Transferred Form of Murine Experimental Autoimmune Encephalomyelitis (1996) (31)
ACTIVATION OF BENZOPORPHYRIN DERIVATIVE IN THE CIRCULATION OF MICE WITHOUT SKIN PHOTOSENSITIVITY (1994) (31)
The effect of haptenic peptides from performic acid oxidized ferredoxin from Clostridium pasteurianum and protein carrier-hapten conjugates on the immune response of macrophages and lymphoid cells from animals immunized against oxidized ferredoxin. (1972) (30)
Photodynamic inactivation of retrovirus by benzoporphyrin derivative: a feline leukemia virus model (1992) (29)
VIP-innervation of rat intestine: A developmental study with monoclonal antibodies (1984) (29)
Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells (1993) (28)
Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. (1997) (28)
Effects of sera from tumor-bearing mice on mitogen and allogeneic cell stimulation of normal lymphoid cells. (1975) (27)
T–T interaction in the generation of helper cells in vitro (1975) (27)
Further characterization of thymic suppressor cells and a factor that suppress the generation of cells cytotoxic for a syngeneic tumor in DBA/2 mice. (1979) (25)
Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems (1992) (24)
Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice. (1976) (24)
Photosensitizing potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. (1996) (23)
A comparison of the ability of serum and monoclonal antibodies to gastric inhibitory polypeptide to detect immunoreactive cells in the gastroenteropancreatic system of mammals and reptiles (2004) (23)
Selective depletion of a thymocyte subset in vitro with an immunomodulatory photosensitizer. (1999) (23)
MODIFIED POLYVINYL ALCOHOL‐BENZOPORPHYRIN DERIVATIVE CONJUGATES AS PHOTOTOXIC AGENTS (1993) (23)
Characterization of a soluble factor that specifically suppresses the in vitro generation of cells cytotoxic for syngeneic tumor cells in mice. (1978) (22)
Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A549-tumor-bearing nude mice. (1993) (21)
Immunological studies on the major haptenic peptides from performic acid oxidized ferredoxin from Clostridium pasteurianum. (1971) (21)
Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative. (1994) (21)
Helper cells active in the generation of cytotoxicity to a syngeneic tumor. (1981) (19)
The cellular immune response to synthetic peptides containing sequences known to be heptenic in performic acid-oxidized ferredoxin from Clostridium pasteurianum. (1972) (19)
Detection of a tumor-associated antigen on the surface of human myelogenous leukemia cells. (1982) (19)
Isolation and characterization of a tumor-specific T suppressor factor from a T cell hybridoma. (1985) (18)
The detection by immunodiffusion of tumour associated antigenic components in extracts of human bronchongenic carcinoma. (1975) (18)
Responses of guinea-pig lymphocytes to mitogens, an antigen, and mixed leucocyte culture in media with and without mercaptoethanol and foetal calf serum. (1975) (17)
Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A (1994) (17)
Cellular and humoral immune responses in guinea pigs and rabbits to chemically defined synthetic peptides (1973) (17)
The Use of Immunoadsorbent Columns for the Isolation of Antibodies Specific for Antigens Associated with Human Bronchogenic Carcinoma (1974) (17)
Characterization of a monoclonal antibody directed to a T cell suppressor factor. (1983) (17)
Clinical status of benzoporphyrin derivative (1996) (17)
Efficacy of benzoporphyrin derivative, a photosensitizer, in selective destruction of leukemia cells using a murine tumor model. (1993) (17)
Evaluation of a model for post-partum arthritis and the role of oestrogen in prevention of MRL-lpr associated rheumatic conditions. (1994) (16)
Photofrin, but not benzoporphyrin derivative, stimulates hematopoiesis in the mouse. (1993) (16)
The Lyt phenotype of cells involved in the cytotoxic response to syngeneic tumor and of tumor-specific suppressor cells. (1980) (16)
SENSITIVITY OF ACTIVATED MURINE PERITONEAL MACROPHAGES TO PHOTODYNAMIC KILLING WITH BENZOPORPHYRIN DERIVATIVE (1995) (16)
Synergism between immune complexes and serum from tumor-bearing mice in the suppression of mitogen responses. (1976) (16)
Monoclonal antibodies to the transforming protein of Fujinami avian sarcoma virus discriminate between different fps-encoded proteins (1984) (15)
Evidence for a common tumour-associated antigen in extracts of human bronchogenic carcinoma. (1977) (15)
A specific helper factor which enhances the cytotoxic response to a syngeneic tumour (1979) (15)
Mode of action of immunosuppressive substances in sera of tumor-bearing mice. (1975) (14)
Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells (2004) (14)
The Relationship of Immune Status to the Efficacy of Immunotherapy in Preventing Tumour Recurrence in Mice (1974) (14)
Immunosuppression of T lymphocyte function by fractionated serum from tumor-bearing mice. (1977) (14)
Isolation of an antigen-specific T suppressor factor that suppresses the in vivo response of DBA/2 mice to ferredoxin. (1987) (13)
Genetic control of the immune response to ferredoxin: linkage and mapping of T cell proliferation and antibody production genes to the MHC of mice. (1980) (13)
Relative sensitivity of leukemic (CML) and normal progenitor cells to treatment with the photosensitizer benzoporphyrin derivative and light. (1993) (13)
Apoptosis associated with esophageal adenocarcinoma: influence of photodynamic therapy. (2001) (12)
Selective elimination of malignant stem cells using photosensitizers followed by light treatment (1995) (12)
Suppression of mitogen responses by serum from tumour-bearing mice. (1974) (12)
Identification of an idiotypic marker of a major regulatory T cell of the immune response in B10.BR mice to ferredoxin. The relationship of idiotypic regulation to conventional hapten-carrier effects (1983) (12)
Reversal of CAMAL-mediated alterations of normal and leukemic in vitro myelopoiesis using inhibitors of proteolytic activity. (1994) (12)
Suppressor cell-inducing factor: a new lymphokine secreted by a natural suppressor cell line with natural cytotoxic activity. I. Purification to apparent homogeneity and initial characterization of suppressor cell-inducing factor. (1988) (11)
Tumour scanning with indium-111 dihaematoporphyrin ether. (1990) (10)
Immunosuppression in mice bearing primary tumors. (1978) (10)
A monoclonal antibody to myelogenous leukemia: isolation and characterization. (1984) (10)
The use of unideterminant fragments of ferredoxin in the genetic mapping of determinant specificity of the immune response. (1982) (10)
Purification of an in vitro inhibitor of normal myelopoiesis using a monoclonal antibody directed to a common antigen of myelogenous leukemia (CAMAL). (1991) (10)
Nononcologic potentials for photodynamic therapy (1994) (9)
Selective binding of chemically defined antigenic peptides to mouse lymphocytes (1974) (9)
Isolation of a T-cell clone that reacts with both antigen and anti-idiotype: evidence for anti-idiotype as internal image for antigen at the T-cell level. (1987) (9)
Effect of photodynamic therapy using benzoporphyrin derivative on the cutaneous immune response (1995) (9)
Preliminary characterization of human T cell suppressor factor (HTsF) isolated from tonsil cells by monoclonal antibody immunoadsorbence. (1985) (9)
Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts. (2000) (9)
Characterization of an anti-idiotypic T cell hybridoma involved in the regulation of the immune response to the P815 mastocytoma. (1986) (9)
The role of suppressor factors in the regulation of immune responses by ultraviolet radiation-induced suppressor T lymphocytes. III. Isolation of a suppressor factor with the B16G monoclonal antibody. (1989) (9)
The Preparation And Application Of Porphyrin-Monoclonal Antibodies For Cancer Therapy (1989) (9)
Analysis of human myelogenous leukemia cells in the fluorescence- activated cell sorter using a tumor-specific antiserum (1983) (9)
Relationship between collagen-induced and adjuvant arthritis in the Lewis rat. (1993) (8)
Immune competence and immunosuppressive factors in splenectomized tumor-bearing mice. (1977) (8)
Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells. (1993) (8)
Kinetics of cellular uptake and retention of the benzoporphyrin derivative (BPD): relevance to photodynamic therapy (1995) (8)
Recovery of immune competence after tumour resection in mice: correlation with loss of suppressor elements. (1978) (8)
The immune response to ferredoxin: characterization of a major idiotype in serum using monoclonal antibody derived by cell fusion. (1982) (8)
A monoclonal antibody raised to tumor-specific T cell-derived suppressor factors also recognizes T suppressor inducer factors of the 4-hydroxy-3-nitrophenyl acetyl hapten suppressor network. (1987) (8)
Preliminary characterization of a soluble immunosuppressive molecule from DBA/2 spleen cells using monoclonal antibody immunoadsorbence. (1985) (7)
Studies on the effector cell of anti-tumour immunity in a chemically induced mouse tumour system. (1975) (7)
Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice. (1980) (7)
Photosensitizer-protein conjugates: potential use as photoimmunotherapeutic agents. (1984) (7)
Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210. (1986) (7)
Detection of tumour-associated antigens in human bronchogenic carcinoma by the enzyme-linked immunosorbent assay (ELISA). (1980) (6)
Photofrin-PDT from Bench to Bedside: Some Lessons Learned (2016) (6)
Effect of adult thymectomy on tumour immunity in mice. (1978) (6)
Partial characterization of a membrane antigen which exhibits specificity for cells of patients with acute myelogenous leukaemia. (1983) (6)
Photofrin increases murine spleen cell transferrin receptor expression and responsiveness to recombinant myeloid and erythroid growth factors. (1998) (6)
The effect of specific cell inactivation on the cellular immune response to ferreodoxin peptides (1975) (6)
Abrogation and reconstitution of nonresponsiveness: a correlation with high network connectivity (1985) (6)
Purification of a protein associated with human bronchogenic squamous-cell carcinoma. (1979) (5)
Detection of a common leukemia-associated antigen in human myelogenous leukemia using immunoperoxidase. (1984) (5)
Photodynamic elimination of clonogenic Ph+ chronic myeloid leukemia cells. (1993) (5)
Transcutaneous photodynamic therapy delays the onset of paralysis in a murine multiple sclerosis model (1994) (5)
Photodynamic Therapy (PDT) and Clinical Applications (2003) (5)
Treatment of experimental murine arthritis with transdermal photodynamic therapy (1994) (5)
Characterization of antigen-binding molecules from T suppressor hybridomas. (1988) (4)
Evidence for the presence of idiotype-bearing regulatory T cells in which idiotype expression does not show linkage to either IgH alleles or the MHC. (1984) (4)
Suppressor deletion therapy. Selective elimination of T suppressor cells using a hematoporphyrin-conjugated monoclonal antibody. (1988) (4)
Immunological effects of photodynamic therapy (1990) (4)
Identity of a T-lymphocyte inhibitor with mouse immunoglobulin in the serum of tumour-bearing mice. (1977) (4)
Immunosuppression of normal lymphoid cells by serum from mice undergoing chronic graft-vs-host disease. (1975) (4)
Intracellular events associated with uptake of a monomeric photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), and its subsequent activation with light (1993) (4)
Analysis of human myelogenous leukemia cells in the fluorescence-activated cell sorter using a tumor-specific antiserum. (1983) (4)
Isolation and partial characterization of immunologically reactive fractions from chitinase digested cell wall of Trichophyton mentagrophytes (1979) (3)
Antigen-specific T-cell hyporesponsiveness in MRL congenic mice can be explained by two independent cellular defects. (1987) (3)
Evidence for a common leukemia-associated antigen in acute myelogenous leukemia (1980) (3)
Differential Uptake Of Benzoporphyrin Derivative (BPD) By Leukemic Versus Normal Cells (1989) (3)
The immune response to oxidized ferredoxin. II. Cross reactivity of cells and antisera to modified ferredoxins and the nature of the cells responding in vitro. (1976) (3)
The immune response to oxidized ferredoxin. I. Specificity of the response to the amino terminal determinant. (1976) (3)
Anti-tumour effects of the sesquiterpene Lactone parthenin. (1982) (3)
Accelerated myelopoietic recovery in irradiated mice treated with Photofrin. (1995) (3)
Monoclonal antibody LR-1 recognizes murine heat-stable antigen, a marker of antigen-presenting cells and developing hematopoietic cells. (1996) (3)
Demonstration of a leukemia-associated antigen (CAMAL) in peripheral blood leucocytes of bone marrow transplant patients prior to relapse. (1985) (3)
Inhibition of murine hematopoiesis by CAMAL, an inhibitor of human hematopoiesis. (1993) (3)
Immune modulation using transdermal photodynamic therapy (1995) (3)
Characterization of immunologically active peptides from the cell wall of T.mentagrophytes (1979) (3)
Production and characterization of high affinity monoclonal antibodies to cyclic anti-depressant molecules. (1987) (3)
Immunobiologic properties of the major antigenic determinants of the ferredoxin molecule. (1978) (3)
Immune Regulation in Neoplasia Dominance of Suppressor Systems (1987) (3)
Effect of Porphyrins on the Hematopoietic Recovery of Mice Treated with γ-Radiation (1994) (2)
Interleukin-12 reverses the inhibitory impact of photodynamic therapy (PDT) on the murine contact hypersensitivity response (1998) (2)
Influence of benzoporphyrin-derivative monoacid ring A (BPD-MA, verteporfin) on murine dendritic cells (1997) (2)
Properties of syngeneic and allogeneic antisera raised to tumor-specific suppressor factor from DBA/2J mice (1981) (2)
The preparation of xenoantiserum specific for a murine mastocytoma cell line (1979) (2)
Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis. (1993) (2)
Immune response to ferredoxin; nonresponder status is not due to suppression. (1984) (2)
Photodynamic therapy. (2022) (2)
Photosensitizers for photodynamic immune modulation (2000) (2)
Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice (2004) (2)
Characteristics of an antigen-specific helper factor that enhances the in vitro generation of cytotoxic cells directed against a syngeneic tumor. (1981) (2)
New Photosensitizers For Photodynamic Therapy (1990) (2)
Clinical Applications of Photodynamic Therapy (2003) (2)
CAMAL: evidence for an inhibitory role in normal granulopoiesis. (1989) (2)
Skin photosensitivity as a model in photodynamic therapy (1996) (2)
Isolation of functional polyclonal TsF from MRL-lpr spleens using monoclonal antibody absorbance. (1986) (1)
Monoclonal antibody to gastric inhibitory polypeptide (1983) (1)
Photodynamic therapy (PDT) as a biological modifier (1996) (1)
Antibodies in the sera of patients with bronchogenic carcinoma that react with antigen from a tumour cell line (1981) (1)
The porphyrin photosensitizer Photofrin elevates murine splenic erythropoiesis. (1998) (1)
Immune Regulation in Neoplasia (1987) (1)
CAMAL: a new prognostic marker for remission in acute nonlymphoblastic leukemia. (1988) (1)
Hematopoietic stimulation by porphyrin photosensitizers (Invited Paper) (1992) (1)
Identification of a T cell subset using a rabbit antibody raised against a T suppressor molecule. (1988) (1)
Cellular co-operation by mouse lymphocytes to chemically defined antigens. (1975) (1)
Tumour-associated antigens in lung cancer: the possibility for a serologic assay. (1980) (1)
Anti-tumor effects of an antiserum raised in syngeneic mice to a tumor-specific T suppressor factor (1982) (1)
Efficacy of photodynamic killing with membrane associated and internalized photosensitizer molecules (1991) (1)
New trends in photobiology (1993) (1)
The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target. (1980) (1)
Improved vision of the eye using photodynamic therapy (1998) (0)
Effects of Anti-Idiotypic Sera (Ab-2) and Monoclonal Idiotypic Antibody (Ab-1) on the Immune Response to a Simple Polypeptide Antigen with only Two Immunologically Active Epitopes. Analysis of the Response at the Unideterminant Level (1983) (0)
Photodynamic therapy for the treatment of overactive sebaceous glands disorders using verteporfin and / or topically applied lemuteporfin (2005) (0)
Activation method of photosensitive agents. (1993) (0)
A process for the activation of the photosensitive means (1993) (0)
Expression of a leukemia-associated antigen (CAMAL) in four myeloid leukemia cell lines. (1988) (0)
Photodynamic treatment with BPD-MA (verteporfin) activated with light within different spectral ranges (1997) (0)
Activation d'agents photosensibles (1993) (0)
An antigen specific helper factor which enhances the cytotoxic t cell response to a syngeneic tumor. Abstr. (1981) (0)
Specific helper factors (1980) (0)
Improved vision in photodynamic therapy of the eye (1997) (0)
226. A comparison of the immunocytochemical staining properties of serum and monoclonal antibodies to gastric inhibitory polypeptide (GIP). (1982) (0)
The Isogeneic Barrier Revisited: Cell Dose Effects and Loss of MHC Control of Responses (2019) (0)
Effect of porphyrins on the hematopoietic recovery of mice treated with gamma-radiation. (1994) (0)
Use of a photosensitizing agent. (1993) (0)
ANTIGEN-SPECIFIC SOLUBLE SUPPRESSOR FACTOR(S) (1980) (0)
Cytotoxic agents specific wavelength. (1989) (0)
The influence of allogeneic or syngeneic cell surface backgrounds on the antibody response of mice to rabbit Fab' fragments. (1977) (0)
Activation of photosensitizers (1993) (0)
Procede d'activitation d'agents photosensibles (1993) (0)
Vision improved by photodynamic therapy of the eye. (1997) (0)
Antigenic Analysis of Human Malignant Myeloid Cells by Immimoperoxidase (1986) (0)
New class of photoactive compounds benzoporphyrin derivatives. (1998) (0)
Traitement therapeutique photodynamique de tumeurs secondaires par immuno-adjuvants (2000) (0)
Influence of Photofrin on the hematopoietic accessory function of murine peritoneal cells. (1997) (0)
IMAGING STUDIES WITH TC‐99M LABELED TUMOR SPECIFIC MONOCLONAL ANTIBODIES TO A TRANSPLANTABLE MURINE TUMOR.: I4 (1983) (0)
Cytotoxic agents having specific wavelength. (1988) (0)
Improvement of the eye unawares by photodynamic therapy (1997) (0)
Immunosuppression of T lymphocyte function by fractionated serum from tumor-bearing mice. (1977) (0)
A new class of photoactive compounds, consisting of benzoporphyrin derivatives (1998) (0)
Methode de prevention du rejet de xenogreffes par therapie photodynamique (1999) (0)
DETEIDlINANTS OF THE FERREDOXIN MOLECULE (1978) (0)
Hydroxy-substituted azetidinone derivatives as HypocWellenlaengenspeziphisches cytoxisches means holesterolemische means (1989) (0)
Compositions and articles to reduce the effects of inflammation. (1998) (0)
Mono clonal antibody specific for myelogenous leukemia (1983) (0)
In the serum of tumour-bearing mice. (1976) (0)
with Photodynamic Therapy Contact Hypersensitivity in Mice Treated IL-10 Contributes to the Inhibition of (2013) (0)
Isolation and characterization of a T-suppressor factor specific for the lupus-associated autoantigen RNP-Sm. (1989) (0)
A GIP monoclonal antibody: Immunocytochemical characterisation (1983) (0)
Preliminary Studies on aMore Effective Phototoxic Agent ThanHematoporphyrin 1 (0)
Äthylenglykolester of monohydrobenzoporphyrinderivaten as the photoactive agent (1998) (0)
Procedure to prevent transplant rejection. (1996) (0)
Photodynamic immune modulation (PIM) (1999) (0)
A method for activating the light-sensitive materials (1995) (0)
The effect of antigen suicide on numbers of cells binding defined antigenic determinants. (1976) (0)
Vision amelioree par therapie photodynamique de l'oeil (1997) (0)
Wavelength {ngenspeziphisches, cytotoxic agent. (1989) (0)
Photodynamic therapy for the treatment of hyperactive sebaceous gland diseases, using verteporfin applied and / or lemuteporfin (2005) (0)
Use Of Green Porphyrinsto Treat Neovasculature In The Eyes (1998) (0)

This paper list is powered by the following services:

Other Resources About Julia Levy

en.wikipedia.org

What Schools Are Affiliated With Julia Levy?

Julia Levy is affiliated with the following schools: